Sugi Predict

Sugi Predict / Targets / FANCI

FANCI

Fanconi anemia group I protein · Q9NVI1 · FANCI on Sugi Atlas →

0 patent compounds predicted against FANCI, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to FANCI by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eltrombopag for People With Fanconi Anemia PHASE2ACTIVE_NOT_RECRUITING
Gene Therapy for Fanconi Anemia, Complementation Group A PHASE2ACTIVE_NOT_RECRUITING
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors PHASE2COMPLETED
Efficacy and Safety of PARPi to Treat Pancreatic Cancer PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
Olaparib in Treating Patients With Stage IV Pancreatic Cancer PHASE2COMPLETED
A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer PHASE2ACTIVE_NOT_RECRUITING
M6620 (VX-970) in Selected Solid Tumors PHASE2COMPLETED
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A PHASE1/PHASE2COMPLETED
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects PHASE2COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors PHASE1COMPLETED
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors PHASE1COMPLETED
Gene Therapy for the Treatment of Fanconi's Anemia Type C PHASE1COMPLETED
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia PHASE1COMPLETED
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer PHASE1ACTIVE_NOT_RECRUITING
Corrective Exercise and Rehabilitation in Fanconi Anemia: A Case Study nanCOMPLETED
Utility of a Urine Screening Tool for Vitamin D Deficiency in Infants and Toddlers nanCOMPLETED
Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy nanACTIVE_NOT_RECRUITING
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations nanCOMPLETED
Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma nanCOMPLETED
Evaluation of Fanconi Syndrome and Cystinosis nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia nanCOMPLETED
Men at High Genetic Risk for Prostate Cancer nanRECRUITING
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base nanRECRUITING
Microcephaly Genetic Deficiency in Neural Progenitors nanCOMPLETED
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FANCI binder may also engage these)

ProteinNameSimilarity
Q8K368 — 1.000 Q8K368 →
Q68Y81 — 1.000 Q68Y81 →
Q99K74 — 0.999 Q99K74 →
Q3UHQ6 — 0.998 Q3UHQ6 →
Q6GPP1 — 0.996 Q6GPP1 →
A5GFY4 — 0.996 A5GFY4 →
B0I564 — 0.996 B0I564 →
B1AY13 — 0.996 B1AY13 →
Q6IV68 — 0.996 Q6IV68 →
USP24 Ubiquitin carboxyl-terminal hydrolase 24 0.995 landscape →
Q8JGR7 — 0.995 Q8JGR7 →
O94915 — 0.994 O94915 →
Q7TPV4 — 0.994 Q7TPV4 →
Q5FWU8 — 0.994 Q5FWU8 →
Q99ML0 — 0.994 Q99ML0 →
A1L2I9 — 0.993 A1L2I9 →
Q640K1 — 0.993 Q640K1 →
Q9YHB5 — 0.993 Q9YHB5 →
Q96N23 — 0.992 Q96N23 →
Q8H0T4 — 0.992 Q8H0T4 →
NUP205 Nuclear pore complex protein Nup205 0.992 landscape →
Q9C0B7 — 0.992 Q9C0B7 →
Q5ZLS8 — 0.992 Q5ZLS8 →
Q80V62 — 0.992 Q80V62 →
Q5TBA9 — 0.992 Q5TBA9 →
Q6ZQK0 — 0.992 Q6ZQK0 →
E9Q8I9 — 0.992 E9Q8I9 →
Q566H4 — 0.992 Q566H4 →
O88480 — 0.991 O88480 →
Q14CX7 — 0.991 Q14CX7 →